Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry
Sandoz’s BLA Accepted For FDA Review In February; Denosumab Sales In Billions
Executive Summary
Months after announcing that its GP2411 biosimilar denosumab candidate was accepted for filing by the FDA, Sandoz has been sued for alleged patent infringement by originator Amgen.
You may also be interested in...
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri
Having previously identified itself as the frontrunner in the race to launch a biosimilar to Amgen’s Prolia, Sandoz has now delivered positive confirmatory data, shortly after being sued in the US over its Polpharma-partnered proposed Tysabri biosimilar.